Research
Molecular
GPR75 is an attractive pharmacological target for the treatment of obesity and metabolic syndrome.
Targeting GPR75 may lead to more effective treatments for obesity and metabolic syndrome.
StrongSupportsmedium confidence
Within this context, the G-protein coupled receptor, GPR75, is an attractive pharmacological target.
Why this rating
The abstract discusses a review of the signaling pathway, indicating a comprehensive analysis.
Source
GPR75: A Newly Identified Receptor for Targeted Intervention in the Treatment of Obesity and Metabolic Syndrome
Michael Fragner et al. · Cardiology in Review · 2024
DOI 10.1097/crd.0000000000000711
reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →